Barth Syndrome Foundation urgently appeals to FDA and Stealth BioTherapeutics to provide access to potential therapy
November 18, 2020In response to FDA’s request for additional clinical trials evaluating elamipretide in individuals with Barth syndrome, BSF rallies the patient community in a global advocacy campaign.
